Allspring Global Investments
ALLO icon

Allspring Global Investments’s Allogene Therapeutics ALLO Stock Holding History

Allspring Global Investments’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,158
Closed -$19.9K – 2770
2022
Q4 		$19.9K Sell
3,158
-70
-2% -$648 ﹤0.01% 2591
2022
Q3 		$34K Buy
+3,228
New +$43.9K ﹤0.01% 2476
2022
Q2 		– Sell
-2,415
Closed -$22K – 2687
2022
Q1 		$22K Sell
2,415
-134
-5% -$1.4K ﹤0.01% 2931
2021
Q4 		$38K Buy
+2,549
New +$45K ﹤0.01% 2869

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Allspring Global Investments's ALLO Position: Q1 2023 in Review

Allspring Global Investments sold out of Allogene Therapeutics (ALLO) in Q1 2023, closing a stake of 3,158 shares — an estimated $19.9K sold.

Allspring Global Investments first reported a position in ALLO in Q4 2021 and held it in 4 quarters. The position peaked at $38K in Q4 2021. 176 funds tracked by Wall St. Rank hold ALLO as of Q1 2023.

  • Allspring Global Investments reported no remaining Allogene Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Allspring Global Investments sold 3,158 Allogene Therapeutics shares in Q1 2023, an estimated $19.9K.
  • Allspring Global Investments first reported a position in Allogene Therapeutics in Q4 2021 and held it in 4 quarters.
  • Allspring Global Investments's Allogene Therapeutics position peaked at $38K in Q4 2021.
  • 176 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2023.

Based on Allspring Global Investments's 13F filing for Q1 2023, filed 13 Apr 2023.